In a regulatory filing, Bruker (BRKR) reports that on January 12, during its scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference, Bruker stated that its current preliminary expectation for revenue for the fourth quarter ended December 31, 2025 is between $965M and $970M and that fourth quarter 2025 Bruker Scientific Instruments segments book-to-bill ratio was above 1.0. The company also provided a preliminary outlook for the full year ending December 31, 2026 of organic revenue growth of flat to up low-single digits, non-GAAP organic operating margins to expand 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits, in each case compared to full year 2025.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker announces $500M multi-year supply agreements for superconductors
- Bruker acquires additional 60% stake in Tofwerk, terms undisclosed
- Bruker price target raised to $53 from $42 at TD Cowen
- Bruker price target raised to $53 from $45 at Guggenheim
- RI Research secures orders for enabling subsystems for gamma ray source of ELI